Related references
Note: Only part of the references are listed.Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease
Paul E. Greene et al.
NPJ PARKINSONS DISEASE (2021)
Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia
Shi-Ying Fan et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Treadmill Exercise Attenuates l-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice
Ana E. Speck et al.
MOLECULAR NEUROBIOLOGY (2019)
CLINICAL TRIAL HIGHLIGHTS 1. GENE THERAPY FOR PARKINSON'S 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA'S ACCORDION PILL 3. CLINICAL TRIALS RESOURCES
Kevin McFarthing et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein
Aki Shimozawa et al.
FRONTIERS IN NEUROSCIENCE (2019)
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse
Elisabetta Tronci et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
The ins and outs of vesicular monoamine transporters
Dana Yaffe et al.
JOURNAL OF GENERAL PHYSIOLOGY (2018)
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
Manolo Carta et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects
Kai Ma et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease A Review
Adolfo Ramirez-Zamora et al.
JAMA NEUROLOGY (2018)
Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin
Irene Ruiz-DeDiego et al.
SCIENTIFIC REPORTS (2018)
Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
Wolfgang Oertel et al.
MOVEMENT DISORDERS (2017)
Regulation profile of the intestinal peptide transporter 1 (PepT1)
Chun-Yang Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
Rajesh Pahwa et al.
JAMA NEUROLOGY (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Dhanya Vijayakumar et al.
DRUGS (2016)
Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
Irene Sebastianutto et al.
NEUROBIOLOGY OF DISEASE (2016)
Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1
Anne-Marie A. Wills et al.
JAMA NEUROLOGY (2016)
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study
Per Svenningsson et al.
BRAIN (2015)
EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
Pablo Martinez-Martin et al.
MOVEMENT DISORDERS (2015)
CURRENT TREATMENT AND FUTURE PROSPECTS OF DOPA-INDUCED DYSKINESIAS
S. Mazzucchi et al.
DRUGS OF TODAY (2015)
Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions
Adolfo Ramirez-Zamora et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2014)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Withdrawing amantadine in dyskinetic patients with Parkinson disease The AMANDYSK trial
Fabienne Ory-Magne et al.
NEUROLOGY (2014)
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations
Manolo Carta et al.
FRONTIERS IN NEUROLOGY (2014)
The Molecular Mechanism of Intestinal Levodopa Absorption and Its Possible Implications for the Treatment of Parkinson's Disease
Simone M. R. Camargo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Markers of Disease Severity Are Associated with Malnutrition in Parkinson's Disease
Jamie M. Sheard et al.
PLOS ONE (2013)
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Gabriele Mittermeyer et al.
HUMAN GENE THERAPY (2012)
Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease
Erik Cederfjall et al.
MOLECULAR THERAPY (2012)
ANIMAL MODELS OF L-DOPA-INDUCED DYSKINESIA: AN UPDATE ON THE CURRENT OPTIONS
H. Iderberg et al.
NEUROSCIENCE (2012)
Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design
David W. Brodell et al.
BMJ OPEN (2012)
Levodopa-Induced-Dyskinesias Clinical Features, Incidence, Risk Factors, Management and Impact on Quality of Life
Alice Manson et al.
JOURNAL OF PARKINSONS DISEASE (2012)
Dosage-dependent non-linear effect of l-dopa on human motor cortex plasticity
Katia Monte-Silva et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
Low-Protein and Protein-Redistribution Diets for Parkinson's Disease Patients with Motor Fluctuations: A Systematic Review
Emanuele Cereda et al.
MOVEMENT DISORDERS (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Clinical Pattern and Risk Factors for Dyskinesias Following Fetal Nigral Transplantation in Parkinson's Disease: A Double Blind Video-Based Analysis
C. Warren Olanow et al.
MOVEMENT DISORDERS (2009)
Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-DOPA-induced dyskinesia
Ana Munoz et al.
BRAIN (2008)
Levodopa-induced dyskinesias in Parkinson's disease: Etiology, impact on quality of life, and treatments
Elmyra V. Encarnacion et al.
EUROPEAN NEUROLOGY (2008)
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
Pedro J. Garcia Ruiz et al.
MOVEMENT DISORDERS (2008)
Advances in understanding L-DOPA-induced dyskinesia
M. A. Cenci et al.
CURRENT OPINION IN NEUROBIOLOGY (2007)
'Rejuvenation' protects neurons in mouse models of Parkinson's disease
C. Savio Chan et al.
NATURE (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
The 6-hydroxydopamine model of Parkinson's disease
Nicola Simola et al.
NEUROTOXICITY RESEARCH (2007)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Pharmacokinetics of L-dopa - Special reference to food and aging
Miho Murata
JOURNAL OF NEUROLOGY (2006)
Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia
N Lundblad et al.
EXPERIMENTAL NEUROLOGY (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
M Lundblad et al.
NEUROBIOLOGY OF DISEASE (2004)
Dyskinesia after fetal cell transplantation for parkinsonism: A PET study
YL Ma et al.
ANNALS OF NEUROLOGY (2002)
Dyskinesias following neural transplantation in Parkinson's disease
P Hagell et al.
NATURE NEUROSCIENCE (2002)
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
CW Olanow et al.
NEUROLOGY (2001)
Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
CR Freed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
BJ Snow et al.
CLINICAL NEUROPHARMACOLOGY (2000)
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
RA Hauser et al.
CLINICAL NEUROPHARMACOLOGY (2000)